ArticleBMC immunology2010

Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Paolo G V Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.